ATE249831T1 - Carboxamidderivate von pyrrolidine und piperidine als urotensin-ii rezeptorantagonisten - Google Patents

Carboxamidderivate von pyrrolidine und piperidine als urotensin-ii rezeptorantagonisten

Info

Publication number
ATE249831T1
ATE249831T1 AT00986598T AT00986598T ATE249831T1 AT E249831 T1 ATE249831 T1 AT E249831T1 AT 00986598 T AT00986598 T AT 00986598T AT 00986598 T AT00986598 T AT 00986598T AT E249831 T1 ATE249831 T1 AT E249831T1
Authority
AT
Austria
Prior art keywords
urotensin
pyrrolidine
piperidine
receptor antagonists
carboxamide derivatives
Prior art date
Application number
AT00986598T
Other languages
English (en)
Inventor
Dashyant Dhanak
Steven David Knight
Jian Jin
Richard Mcculloch Keenan
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE249831T1 publication Critical patent/ATE249831T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AT00986598T 1999-12-21 2000-12-19 Carboxamidderivate von pyrrolidine und piperidine als urotensin-ii rezeptorantagonisten ATE249831T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17290799P 1999-12-21 1999-12-21
PCT/US2000/034579 WO2001045711A1 (en) 1999-12-21 2000-12-19 Urotensin-ii receptor antagonists

Publications (1)

Publication Number Publication Date
ATE249831T1 true ATE249831T1 (de) 2003-10-15

Family

ID=22629697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00986598T ATE249831T1 (de) 1999-12-21 2000-12-19 Carboxamidderivate von pyrrolidine und piperidine als urotensin-ii rezeptorantagonisten

Country Status (7)

Country Link
US (1) US6544992B1 (de)
EP (1) EP1244452B1 (de)
JP (1) JP2003518065A (de)
AT (1) ATE249831T1 (de)
DE (1) DE60005401T2 (de)
ES (1) ES2207566T3 (de)
WO (1) WO2001045711A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1310490A4 (de) * 2000-07-04 2004-03-17 Takeda Chemical Industries Ltd Gpr14-antagonisten
WO2002015934A1 (fr) * 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Agents prophylactiques et remedes contre des maladies du systeme nerveux central
IL157093A0 (en) * 2001-03-27 2004-02-08 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
JP2004529134A (ja) * 2001-03-29 2004-09-24 スミスクライン・ビーチャム・コーポレイション ピロリジンスルホンアミド
US6999972B2 (en) 2001-09-08 2006-02-14 Siemens Medical Systems Health Services Inc. System for processing objects for storage in a document or other storage system
CA2473892C (en) * 2001-12-04 2010-09-21 Actelion Pharmaceuticals Ltd Novel quinoline derivatives
WO2003104216A1 (en) * 2002-06-10 2003-12-18 Acadia Pharmaceuticals Inc. Urotensin ii receptor modulators
US7262207B2 (en) * 2002-09-19 2007-08-28 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20040121964A1 (en) * 2002-09-19 2004-06-24 Madar David J. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7238724B2 (en) * 2002-09-19 2007-07-03 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
EP1565436B1 (de) 2002-11-27 2012-04-25 Incyte Corporation 3-aminopyrrolidinderivate als modulatoren von chemokinrezeptoren
WO2005019168A2 (en) * 2003-08-20 2005-03-03 Pfizer Products Inc. Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
AU2004275488A1 (en) 2003-09-26 2005-04-07 Actelion Pharmaceuticals Ltd Pyridine derivatives and use thereof as urotensin II antagonists
US20070238753A1 (en) * 2004-02-27 2007-10-11 Madar David J Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV)
BRPI0515979A (pt) 2004-10-12 2008-08-12 Actelion Pharmaceuticals Ltd composto, processo para a preparação do mesmo, composições, uso de um ou mais compostos, e, método de tratamento de um paciente sofrendo de um distúrbio
CL2007002097A1 (es) * 2006-07-20 2008-01-18 Smithkline Beecham Corp Compuestos derivados de pirrolidina o morfolina antagonistas de urotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar insuficiencia cardiaca congestiva, insuficiencia cardiaca isquemica, angina, isquemia del miocardio, vejiga hiperactiva, asma y/o copd, entre otras.
WO2008016534A1 (en) * 2006-07-31 2008-02-07 Janssen Pharmaceutica, N.V. Urotensin ii receptor antagonists
TW200927101A (en) * 2007-10-18 2009-07-01 Speedel Experimenta Ag Trisubstituted piperidines
ATE546448T1 (de) * 2008-08-02 2012-03-15 Janssen Pharmaceutica Nv Urotensin-ii-rezeptorantagonisten
WO2013005168A2 (en) * 2011-07-05 2013-01-10 Lupin Limited Cannabinoid receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1425559A (en) * 1972-09-01 1976-02-18 Wyeth John & Brother Ltd Pyridine tetrahydropyridine and piperidine derivatives
GB1520584A (en) * 1975-04-02 1978-08-09 Yamanouchi Pharma Co Ltd 2 - alkoxy - 5 substituted benzamide derivatives and their use in pharmaceutical compositions
US5210090A (en) * 1989-09-05 1993-05-11 G. D. Searle & Co. Substituted N-benzylpiperidine amides and cardiac regulatory compositions thereof

Also Published As

Publication number Publication date
EP1244452B1 (de) 2003-09-17
EP1244452A1 (de) 2002-10-02
DE60005401T2 (de) 2004-05-06
WO2001045711A1 (en) 2001-06-28
US6544992B1 (en) 2003-04-08
EP1244452A4 (de) 2003-01-15
JP2003518065A (ja) 2003-06-03
ES2207566T3 (es) 2004-06-01
DE60005401D1 (de) 2003-10-23

Similar Documents

Publication Publication Date Title
DE60005401D1 (de) Carboxamidderivate von pyrrolidine und piperidine als urotensin-ii rezeptorantagonisten
MXPA04002982A (es) Derivados de pirrolidinona.
DE60142921D1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
ATE386023T1 (de) Pyrrolidin und piperidinderivate als nk1 antagonisten
ATE300533T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate als urotensin ii rezeptor-antagonisten
IL166271A0 (en) Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same
DK1499607T3 (da) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-quinoliner som urotensin II-receptorantagonister
HUP0203528A3 (en) Piperidine derivatives useful as ccr5 antagonists, pharmaceutical compositions containing them and their use
CH1175401H1 (de) Piperazin Derivate verwendbar als CCR5 Antagonisten
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
ATE311363T1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
DE602004006433D1 (de) Pyrrol-substituierte indole als inhibitoren von pai-1
ATE328879T1 (de) Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv
MXPA03010158A (es) Sulfonamidas.
ATE178886T1 (de) 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
DE60037183D1 (de) Neue amidinbenzylamin-derivate und ihre verwendung als thrombin-inhibitoren
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE266722T1 (de) Zyklische peptidomimetische urokinaserezeptorantagonisten
DE60015187D1 (de) Urotensin-ii rezeptorantagonisten
ATE235466T1 (de) Heterozyklen zur behandlung von gutartiger prostata-hyperplasie und deren zwischenprodukte
BRPI0409958A (pt) quinolinas de benzofuranil- e benzotienil-piperazinil quinolinas e métodos para o seu uso
ATE282041T1 (de) Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist
DE69320352D1 (de) Piperidinylamide, sulfonamide und sulfoxamide als inhibitoren der cholesterin biosynthese
DE69526738D1 (de) Endothelin-rezeptor-antagonisten
ATE450527T1 (de) Piperidinderivate als ccr5-inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties